Imipenem/Relebactam Resistance in Clinical Isolates of Extensively Drug Resistant Pseudomonas aeruginosa: Inhibitor-Resistant β-Lactamases and Their Increasing Importance-Reference-Cited by-同舟云学术

Imipenem/Relebactam Resistance in Clinical Isolates of Extensively Drug Resistant Pseudomonas aeruginosa: Inhibitor-Resistant β-Lactamases and Their Increasing Importance

Published:2022-05-17 Issue:5 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Hujer Andrea M.¹²,Bethel Christopher R.²,Taracila Magdalena A.¹²,Marshall Steven H.²,Rojas Laura J.¹²,Winkler Marisa L.²³,Painter Ronald E.⁴,Domitrovic T. Nicholas¹²,Watkins Richard R.⁵,Abdelhamed Ayman M.⁶⁷,D’Souza Roshan⁸^ORCID,Mack Andrew R.³^ORCID,White Richard C.⁸,Clarke Thomas⁸,Fouts Derrick E.⁸^ORCID,Jacobs Michael R.⁶⁷^ORCID,Young Katherine⁴,Bonomo Robert A.¹²³⁹¹⁰^ORCID

Affiliation:

1. Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

2. Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA

3. Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

4. Merck & Co., Inc., Kenilworth, New Jersey, USA

5. Division of Infectious Diseases, Cleveland Clinic Akron General, Akron, Ohio, USA

6. Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA

7. Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA

8. J. Craig Venter Institute, Rockville, Maryland, USA

9. Departments of Biochemistry, Pharmacology, and Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA

10. Senior Clinician Scientist Investigator, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA

Abstract

Multidrug-resistant (MDR) Pseudomonas aeruginosa infections are a major clinical challenge. Many isolates are carbapenem resistant, which severely limits treatment options; thus, novel therapeutic combinations, such as imipenem-relebactam (IMI/REL), ceftazidime-avibactam (CAZ/AVI), ceftolozane-tazobactam (TOL/TAZO), and meropenem-vaborbactam (MEM/VAB) were developed.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

U.S. Department of Veterans Affairs

U.S. Department of Health and Human Services

Merck & Co. | Merck Sharp and Dohme

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01790-21

Reference63 articles.